Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by O12009on Aug 30, 2021 8:14pm
308 Views
Post# 33786040

RE:RE:Prelim Results

RE:RE:Prelim Results

99942Apophis wrote: monte2016 wrote
There is a graph with incomplete prelim results.  For those that are experienced in these biotech plays...what is your opinion on these results?  90 day shows 33.3 CR and that is down to 11.1 for 360 days and 450. Are these numbers high enough for CR to excite the medical community?  Your thoughts would be appreciated. Thanks.


The numbers at 360 & 450 are of the first 12 patients whom were under treated so speaking for myself anyone in that group that had CR or partial CR was amazing (plus 3 from Ph1). My attention will solely be focused on all patients after those 12 as to me they are the ones that received the optimized treatment and will truly be representative of this study.
Going forward monte2016 I expect continued improvement in those charts.

 



If you search on their web site for news letter you can see the results for the last six that were treated with the optimize treatment.

2 complete response 33.3%
1 no response 16.7%
3 pending 50%

so it is possible at 90 days if the last 3 were CR we could be as high as 83.3% CR.
if 2 of the last 3 were CR we would be 66.7 CR
if 1 of the last 3 were CR we would be 50% CR
 

<< Previous
Bullboard Posts
Next >>